Results 31 to 40 of about 87,437 (368)

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Leukemia, 2018
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or ...
J. Cortes, Florian H. Heidel, A. Hellmann, W. Fiedler, B. Smith, T. Robak, P. Montesinos, D. Pollyea, P. Desjardins, O. Ottmann, W. Ma, M. N. Shaik, A. Laird, M. Zeremski, A. O’Connell, G. Chan, M. Heuser   +16 more
semanticscholar   +1 more source

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Haematologica, 2020
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem cell transplant (auto-PBSCT) predicts progression-free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL).
M. Kersten, J. Driessen, J. Zijlstra, W. Plattel, F. Morschhauser, P. Lugtenburg, P. Brice, M. Hutchings, T. Gastinne, Roberto D. K. Liu, C. Burggraaff, M. Nijland, S. Tonino, A. Arens, R. Valkema, H. van Tinteren, M. Lopez-Yurda, A. Diepstra, D. de Jong, A. Hagenbeek   +19 more
semanticscholar   +1 more source

Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells

International Journal of Molecular Sciences, 2021
Over half of older patients with acute myeloid leukemia (AML) do not respond to cytotoxic chemotherapy, and most responders relapse because of drug resistance. Cytarabine is the main drug used for the treatment of AML.
Shuo Wang, Yin-Hwa Shih, Tzong-Ming Shieh, Yu-Hsin Tseng   +3 more
semanticscholar   +1 more source

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

BMC Cancer, 2018
Background The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance.
Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman, Sara Ek   +8 more
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.

Future Oncology, 2020
Patients with refractory or relapsed acute myeloid leukemia (R/R AML) have a poor prognosis, with a high unmet medical need. Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53.
P. Montesinos, Benjamin M. Beckermann, O. Catalani, J. Esteve, K. Gamel, M. Konopleva, G. Martinelli, Annabelle Monnet, C. Papayannidis, Aaron Park, C. Récher, R. Rodríguez-Veiga, C. Röllig, N. Vey, A. Wei, S. Yoon, P. Fenaux   +16 more
semanticscholar   +1 more source

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

Haematologica, 2019
Although cytarabine has been widely considered as one of the chemotherapy drugs for high-risk myelodysplastic syndromes (MDS), the overall response rate is only approximately 20-30%.
Peipei Lin, Yanling Ren, Xiaomei Yan, Yingwan Luo, Hua Zhang, Meenu Kesarwani, Jiachen Bu, Di Zhan, Yile Zhou, Yuting Tang, Shuanghong Zhu, Weilai Xu, Xinping Zhou, Chen Mei, Liya Ma, Li Ye, Chao Hu, Mohammad Azam, Wei Ding, Jie Jin, Gang Huang, Hongyan Tong   +21 more
doaj   +1 more source

MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism [PDF]

, 2018
Acute myeloid leukaemia (AML) is an aggressive haematological malignancy with an unmet need for improved therapies. Responses to standard cytotoxic therapy in AML are often transient because of the emergence of chemotherapy-resistant disease.
Anastasiadou, Eleni, Avigan, David, Bar-Natan, Michal, Cole, Leandra, Coll, Maxwell D., Ephraim, Adam, Jain, Salvia, Kharbanda, Akriti, Kufe, Donald, Kufe, Turner, Leaf, Rebecca K., Nahas, Myrna, Orr, Shira, Palmer, Kristen, Pyzer, Athalia, Rahimian, Maryam, Rajabi, Hasan, Rosenblatt, Jacalyn, Stroopinsky, Dina, Tagde, Ashujit, Washington, Abigail   +20 more
core   +1 more source

EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.

The Oncologist, 2020
On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyxeos, intended for the treatment of acute myeloid leukemia (AML).
Kyriaki Tzogani, K. Penttilä, Tuomo Lapveteläinen, R. Hemmings, J. Koenig, J. Freire, Silva Márcia, S. Cole, P. Coppola, Beatriz Flores, Y. Barbáchano, Silvia Domingo Roige, F. Pignatti   +12 more
semanticscholar   +1 more source